Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics

An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC)

(2017) H. S. Pandha et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized phase II trial of two dosing schedules of BI 2536, a novel Plk-1 inhibitor, in patients with relapsed advanced or metastatic non-small-cell lung cancer (NSCLC)

(2017) J. Von Pawel et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of antisense RNA targeting Polo-like kinase 1 on cell growth in A549 lung cancer cells

(2010) Qiong Zhou et al.   Journal of Huazhong University of Science and Technology-Medical Sciences

Distinct Concentration-Dependent Effects of the Polo-like Kinase 1-Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis

(2009) A. G. Gilmartin et al.   CANCER RESEARCH

Identification and Validation of a Potent Type II Inhibitor of Inactive Polo-like Kinase 1

(2009) Sarah Keppner et al.   ChemMedChem

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

(2009) D. Rudolph et al.   CLINICAL CANCER RESEARCH

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology

(2009) P. Schoffski   ONCOLOGIST

Polo-like Kinase 3 Functions as a Tumor Suppressor and Is a Negative Regulator of Hypoxia-Inducible Factor-1  under Hypoxic Conditions

(2008) Y. Yang et al.   CANCER RESEARCH

Inhibition of Polo-like Kinase 1 by Blocking Polo-Box Domain-Dependent Protein-Protein Interactions

(2008) Wolfgang Reindl et al.   CHEMISTRY & BIOLOGY

Polo on the Rise—from Mitotic Entry to Cytokinesis with Plk1

(2008) Mark Petronczki et al.   DEVELOPMENTAL CELL

430 POSTER Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer

(2008) D. Rudolph et al.   EJC SUPPLEMENTS

36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours

(2008) P. Schöffski et al.   EJC SUPPLEMENTS

Deficiency in Chromosome Congression by the Inhibition of Plk1 Polo Box Domain-dependent Recognition

(2008) Nobumoto Watanabe et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery

(2008) Libor Macůrek et al.   NATURE

Bora and the Kinase Aurora A Cooperatively Activate the Kinase Plk1 and Control Mitotic Entry

(2008) A. Seki et al.   SCIENCE